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http://dx.doi.org/10.1016/j.bbmt.2013.06.020onor HLA-Identical or
HLA-Haploidentical Allogeneic Blood or Marrow Trans-
plantation for Peripheral T Cell Lymphoma” [Kanakry et al., Biol
Blood Marrow Transplant 2013;19:602-606], the funding
acknowledgment to be included is: This work was supported
by P01CA15396 and P50CA96888 from the National Cancer
Institute and T32HL7525 from the National Institutes of Health.DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2012.10.029.In ‘‘Autologous Stem Cell Transpl
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http://dx.doi.org/10.1016/j.bbmt.2013.04.024antation for Refractory or
Poor-Risk Relapsed Hodgkin’s Lymphoma: Effect of the
Speciﬁc High-Dose Chemotherapy Regimen on Outcome”
[Nieto et al., Biol Blood Marrow Transplant 2013:19:410], the
following author was inadvertently omitted from the
submitted manuscript: Patricia S. Fox, MS, Department of
Biostatistics, MD Anderson Cancer Center, Orlando, FL.DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2012.09.020.In ‘‘Cancer Vaccines and T Cell
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http://dx.doi.org/10.1016/j.bbmt.2013.03.005Therapy” [Rezvani et al.,
Biol BloodMarrow Transplant 2013:19:S97-S101], the author
afﬁliations are corrected as follows:
Katayoun Rezvani1,*, Joshua D. Brody2, Holbrook E. Kohrt3,
Aaron C. Logan3, Ranjana Advani3, Debra Katherine Czer-
winski3,Wen-KaiWeng3, Robert S. Negrin3, Victoria Carlton4,
Malek Faham4, Ronald Levy3, John Barrett5
1Department of Stem Cell Transplantation and Cellular
Therapy, University of Texas M.D. Anderson Cancer Center,
Houston, Texas
2Lymphoma Immunotherapy Program, Mount Sinai
School of Medicine, New York, New York
3Department of Medicine, Stanford University Medical
Center, Stanford, California
4Sequenta, Inc, South San Francisco, California
5Stem Cell Transplantation Section, Hematology Branch,
National Heart, Lung, and Blood Institute, National Institutes
of Health, Bethesda, MarylandDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2012.10.020.In ‘‘Viewing Transplantation
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http://dx.doi.org/10.1016/j.bbmt.2013.01.025Immunology through
Today’s Lens: New Models, New Imaging, and New Insights”
[Kean et al., Biol Blood Marrow Transplant 2013;19:S44-S51],
in the Acknowledgments section the NCI grant “R01
CA171523” should read “R01 CA154656”.DOI of original article: http://dx.doi.org/10.1016/j.bbmt.2012.11.004.In “Allogeneic Transplantation
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http://dx.doi.org/10.1016/j.bbmt.2013.01.012: When Is a Mismatch
Better Than a Match?” [Shaw et al., Biol Blood Marrow
Transplant 2013:19:1-2], “Anthony Nolan” should not be
listed as an author. Dr. Bronwen Shaw’s afﬁliation should
read, “Anthony Nolan, UCL Cancer Centre and Royal Marsden
NHS Foundation Trust, London, United Kingdom.”
